Combined Postcapillary PH in Scleroderma and HFpEF
62-year-old woman with limited cutaneous systemic sclerosis and HFpEF (LVEF 60%) presents with 3 months of exertional dyspnea and leg swelling. Echo: RVSP 58 mmHg, TAPSE 14 mm, moderate TR, and LA enlargement. Right heart catheterization: RA 14 mmHg, mPAP 42 mmHg, PCWP 20 mmHg, CO 4.0 L/min, CI 2.0 L/min/m2, PVR 5.5 WU. She is on furosemide 40 mg daily; BP 108/64, creatinine 1.2 mg/dL, NT-proBNP 1,200 pg/mL. HRCT shows no interstitial lung disease. She has no digital ulcers and no history of pulmonary embolism.
1. How would you classify her pulmonary hypertension, and what does the PVR add?
Read the worked answer
Her mPAP is 42 mmHg, PCWP 20 mmHg, and PVR 5.5 WU, so she has combined postcapillary and precapillary pulmonary hypertension, not group 1 PAH. The elevated PCWP places her in the postcapillary category, and the PVR above 3 WU (well above the newer 2 WU threshold) indicates a precapillary component with intrinsic pulmonary vascular disease. The TPG is 22 mmHg. This matters because PAH-specific therapies are not routinely approved for group 2 or combined PH, and vasodilators can precipitate pulmonary edema when the left heart is the driving lesion. Her low CI and TAPSE 14 mm also indicate right ventricular dysfunction. I would confirm the wedge position and review the pressure tracing before final classification.
2. Would you start a pulmonary vasodilator now? What would you do first?
Read the worked answer
I would not start an endothelin receptor antagonist or riociguat routinely in combined postcapillary PH. First optimize decongestion with diuretics, treat HFpEF with an SGLT2 inhibitor, control BP, and treat any AF. Reassess after volume optimization because PCWP and PVR can change. If she remains with severe right heart failure and markedly elevated PVR despite a dry profile, refer to a PH center for individualized consideration of a PDE5 inhibitor; this is off-label and requires close monitoring for pulmonary edema and systemic hypotension. Avoid calcium channel blockers unless she has documented vasoreactivity, which is not established here. Her scleroderma does not automatically mean group 1 PAH when PCWP is 20 mmHg.
3. What are the key right-heart management issues, and what would make you reconsider the diagnosis?
Read the worked answer
Manage right heart failure with cautious diuresis, oxygen to keep saturation >90%, avoidance of systemic hypotension, and correction of anemia and arrhythmia. If CI is low and perfusion is marginal, short-term inotropes may be necessary, but they can worsen arrhythmia. Reconsider group 1 PAH if a repeat right heart cath off diuretics shows PCWP <=15 mmHg with PVR >2 WU, or if the wedge pressure is unreliable. Also screen for CTEPH with V/Q scan if there is any thromboembolic history, and evaluate for scleroderma renal crisis if BP rises. A fluid challenge is not needed when PCWP is clearly 20 mmHg; it could worsen edema. Her no ILD history lowers the chance of group 3 PH.